Gene Therapy Casgevy denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for gene therapy casgevy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Casgevy as Duplicate Therapy — and Why That Is Wrong

A "duplicate therapy" denial means UnitedHealthcare's system detected that you are currently receiving or have recently received another treatment it considers equivalent to Casgevy. For a gene therapy, this is almost never clinically accurate: Casgevy is a one-time CRISPR-based gene editing treatment with a fundamentally different mechanism than any ongoing pharmacologic therapy such as hydroxyurea or a transfusion program. The duplicate-therapy flag is typically a billing or utilization-management system error, not a genuine clinical finding.

## Why This Denial Is Appealable

A denial grounded in a factual error — that Casgevy is the same as a drug you are already receiving — is one of the strongest bases for appeal. Under ACA §2719 and ERISA §503, UHC must conduct a full-and-fair review that considers the actual clinical facts. An IRO will not uphold a duplicate-therapy denial if the record shows the two treatments are mechanistically and clinically distinct.

## Federal Appeal Framework

• Immediate peer-to-peer call: Your hematologist should request a peer-to-peer with UHC's medical director to clarify that Casgevy and any current therapy are not therapeutically duplicative.
• Internal appeal: Submit within the timeframe on the denial notice with documentation distinguishing Casgevy from current treatments.
• External review: If internal appeal is denied, request IRO review within approximately four months of the final denial.
• Expedited review: Available when delay would jeopardize health.

## Documentation to Gather

1. Current medication list: A complete list of all current treatments with start dates, to show what therapy UHC identified as the duplicate. 2. FDA prescribing labels for both treatments: Show that Casgevy's mechanism of action (gene editing) is categorically different from any ongoing pharmacologic therapy. 3. Hematologist letter: A letter from your treating hematologist explicitly explaining why Casgevy is not a duplicate of any current therapy — mechanistically, clinically, and in terms of treatment goal. 4. Claim/coding review: Ask the treatment center's billing team to verify there is no coding overlap creating the false duplicate flag. 5. UHC policy identification: Obtain the specific UHC policy the denial cites and confirm whether it addresses gene therapy explicitly.

## Criteria-Mapping Strategy

The mapping exercise here is a rebuttal: identify what UHC claimed was the duplicate, then document the clinical distinction point by point. Gene therapy targeting the root genetic cause of disease is not duplicative of supportive or disease-managing pharmacotherapy. Make that argument explicitly, with the FDA label and your hematologist's clinical opinion as the evidentiary anchors.